GlassScriptPhysician profile
Alexander C Roby
NPI 1144585639
$1,767.87
in general payments reported to CMS, 2019-2025
18 companies · $767 in 2025
The $767 reported for 2025 was more than what 81% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $423 · 2024: $578 · 2025: $767.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,768.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,767.87 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $397.99 | 2023-2025 | Vraylar, Ubrelvy, Qulipta |
| Pfizer INC. | $247.99 | 2023-2025 | |
| Lilly USA, LLC | $247.55 | 2023-2025 | Mounjaro, Zepbound, Jardiance |
| Astrazeneca Pharmaceuticals LP | $237.60 | 2024-2025 | Breztri, Farxiga, Airsupra |
| Exact Sciences Corporation | $136.08 | 2024-2025 | Cologuard Collection Kit |
| Glaxosmithkline, LLC. | $84.16 | 2023-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Boehringer Ingelheim Pharmaceuticals, INC. | $75.90 | 2023-2025 | Jardiance |
| Lundbeck LLC | $68.63 | 2024 | Rexulti |
| Astellas Pharma US INC | $43.48 | 2025 | Veozah |
| Phathom Pharmaceuticals, INC. | $38.02 | 2025 | Voquezna |
| Abbott Laboratories | $34.36 | 2024-2025 | Freestyle Libre 3 |
| Novo Nordisk INC | $29.25 | 2024-2025 | Ozempic, Rybelsus |
| Inari Medical, INC. | $25.01 | 2024 | Ct Thrombectomy System Kit, Flowtriever Catheter, S |
| Axsome Therapeutics, INC. | $23.93 | 2025 | Symbravo |
| Radius Health, INC. | $22.48 | 2025 | Tymlos |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sumitomo Pharma America, INC. | $20.46 | 2025 | Gemtesa |
| Alk-Abello, INC | $18.28 | 2024 | Grastek, Odactra, Ragwitek |
| Currax Pharmaceuticals LLC | $16.70 | 2023 | Contrave, Nexlizet, Nexletol |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alexander Roby listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.